Anthropic partnered with six life sciences firms to accelerate drug development. It also launched its own programs for rare childhood muscular dystrophy. Generate Biomedicines used Claude to design a shorter, more effective CAR T-cell therapy component. Divergence Labs generated 35,000 antibody designs in a month for food allergy treatments. BigHat Biosciences improved drug leads with Claude, achieving 10x tighter binding and 100x slower clumping. Enveda reduced document review time by 89% and drafted regulatory filings faster. The Column Group is founding Pleiades to scale drug programs using Claude. Bristol Myers Squibb is using Claude to assess clinical trial plans. Anthropic acquired Mithril Medicine to advance muscular dystrophy treatments. Its first drug candidate may enter human trials by late 2028. Anthropic offers Claude Science, credits, and a verification program for life sciences. It also launched an open call for guest investigators in the field.
What changed
Drug development tasks were handled manually or with limited AI assistance.
What it unlocks
AI-driven acceleration of drug discovery, design, optimization, manufacturing, and regulatory processes across multiple disease areas.
- 70% shorter design
- 10x more receptors
- 35,000 antibody designs in ~1 month
- 1,010 variants in ~10 weeks
What you need to act on it
- access to Claude Science or verified life sciences models
- partnership with Anthropic or its collaborators
Sources